Outpatient Intravenous Remdesivir to Prevent Progression to Severe COVID-19: An Observational Study from a Greek Hospital.
Nikolaos KintrilisIosif Galinos
Published in: Recent advances in anti-infective drug discovery (2023)
Among non-hospitalized patients with at least one risk factor for progression to severe COVID-19, a 3-day course of intravenous remdesivir yielded favourable results.